NASDAQ:TLSI TriSalus Life Sciences (TLSI) Stock Price, News & Analysis $5.48 -0.09 (-1.62%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$5.47 -0.01 (-0.16%) As of 05/29/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About TriSalus Life Sciences Stock (NASDAQ:TLSI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get TriSalus Life Sciences alerts:Sign Up Key Stats Today's Range$5.35▼$5.6050-Day Range$4.90▼$5.7452-Week Range$3.50▼$7.75Volume35,823 shsAverage Volume42,324 shsMarket Capitalization$176.85 millionP/E RatioN/ADividend YieldN/APrice Target$10.75Consensus RatingBuy Company OverviewTriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.Read More… TriSalus Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreTLSI MarketRank™: TriSalus Life Sciences scored higher than 53% of companies evaluated by MarketBeat, and ranked 548th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingTriSalus Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTriSalus Life Sciences has only been the subject of 1 research reports in the past 90 days.Read more about TriSalus Life Sciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for TriSalus Life Sciences are expected to grow in the coming year, from ($1.55) to ($0.61) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TriSalus Life Sciences is -2.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TriSalus Life Sciences is -2.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about TriSalus Life Sciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.69% of the float of TriSalus Life Sciences has been sold short.Short Interest Ratio / Days to CoverTriSalus Life Sciences has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TriSalus Life Sciences has recently increased by 206.18%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTriSalus Life Sciences does not currently pay a dividend.Dividend GrowthTriSalus Life Sciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.69% of the float of TriSalus Life Sciences has been sold short.Short Interest Ratio / Days to CoverTriSalus Life Sciences has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TriSalus Life Sciences has recently increased by 206.18%, indicating that investor sentiment is decreasing significantly. News and Social Media1.6 / 5News Sentiment-0.14 News SentimentTriSalus Life Sciences has a news sentiment score of -0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for TriSalus Life Sciences this week, compared to 1 article on an average week.MarketBeat Follows7 people have added TriSalus Life Sciences to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, TriSalus Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $83,528.00 in company stock.Percentage Held by Insiders27.50% of the stock of TriSalus Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 2.58% of the stock of TriSalus Life Sciences is held by institutions.Read more about TriSalus Life Sciences' insider trading history. Receive TLSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TriSalus Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address TLSI Stock News HeadlinesJodi Devlin Sells 4,764 Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) StockMay 22, 2025 | insidertrades.comRoth Capital Issues Pessimistic Estimate for TLSI EarningsMay 25, 2025 | americanbankingnews.comBuffett’s Next Move Could Shock Wall StreetIn just a few weeks, a move decades in the making could be revealed — and when it is, it could ignite the next great gold rush. Savvy insiders are quietly positioning now… before Buffett makes it official. Garrett Goggin has already pinpointed four tiny-gold-miners that could 100X once the announcement hits. It’s the perfect moment to be greedy — before the herd wakes up.May 30, 2025 | Golden Portfolio (Ad)Cantor Fitzgerald Has Negative View of TLSI FY2025 EarningsMay 23, 2025 | americanbankingnews.comTriSalus outlines at least 50% revenue growth for 2025 as new Medicare code expands addressable marketMay 15, 2025 | msn.comTriSalus Life Sciences, Inc. (TLSI) Q1 2025 Earnings Conference Call TranscriptMay 15, 2025 | seekingalpha.comTriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 GuidanceMay 15, 2025 | businesswire.comTriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference CallMay 12, 2025 | businesswire.comSee More Headlines TLSI Stock Analysis - Frequently Asked Questions How have TLSI shares performed this year? TriSalus Life Sciences' stock was trading at $5.01 at the beginning of the year. Since then, TLSI stock has increased by 9.4% and is now trading at $5.48. View the best growth stocks for 2025 here. How were TriSalus Life Sciences' earnings last quarter? TriSalus Life Sciences, Inc. (NASDAQ:TLSI) posted its quarterly earnings results on Thursday, May, 15th. The company reported ($0.33) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by $0.13. The business had revenue of $9.17 million for the quarter, compared to analysts' expectations of $9.04 million. Read the conference call transcript. Who are TriSalus Life Sciences' major shareholders? Top institutional shareholders of TriSalus Life Sciences include Goldman Sachs Group Inc. (0.11%) and Charles Schwab Investment Management Inc. (0.03%). Insiders that own company stock include Equity Ab Frankenius, Mary T Szela, George Kelly Martin, Sean Murphy, Bryan F Cox, Richard Marshak, Jodi Devlin, James Emmett Young and Mats Wahlstrom. View institutional ownership trends. How do I buy shares of TriSalus Life Sciences? Shares of TLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of TriSalus Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that TriSalus Life Sciences investors own include AutoZone (AZO), Intel (INTC), Meta Platforms (META), Merck & Co., Inc. (MRK), TJX Companies (TJX), Abacus Health Products (ABAHF) and Airbnb (ABNB). Company Calendar Last Earnings5/15/2025Today5/30/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:TLSI Previous SymbolNASDAQ:TLSI CIK1826667 Webtrisaluslifesci.com Phone888-321-5212FaxN/AEmployees106Year FoundedN/APrice Target and Rating Average Stock Price Target$10.75 High Stock Price Target$12.50 Low Stock Price Target$10.00 Potential Upside/Downside+96.2%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$59.04 million Net Margins-206.24% Pretax Margin-205.69% Return on EquityN/A Return on Assets-236.83% Debt Debt-to-Equity RatioN/A Current Ratio2.40 Quick Ratio2.00 Sales & Book Value Annual Sales$32.14 million Price / Sales5.50 Cash FlowN/A Price / Cash FlowN/A Book Value($0.98) per share Price / Book-5.59Miscellaneous Outstanding Shares32,272,000Free Float20,491,000Market Cap$176.85 million OptionableNot Optionable Beta0.50 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:TLSI) was last updated on 5/30/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TriSalus Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TriSalus Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.